TB Vaccines for the World

23-25 May 2012, Buena Vista Palace Hotel, Orlando, Florida, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 23rd May

09.00-09.10
Welcome & Opening Remarks
Ian M. Orme (Colorado State University, Colorado, USA)

SESSION 1:
OPENING PLENARY SESSION I

Moderator: Helen McShane (University of Oxford, Oxford, UK)

09.10-09.40
KEYNOTE LECTURE:
‘BCG myths and realities’

David N. McMurray (Texas A&M University, College Station, Texas, USA)

09.40-10.10
‘Current TB vaccine trial status’
Ann Ginsberg (AERAS, Rockville, Maryland, USA)

10.10-10.40
‘The immune response to TB’
Andrea M. Cooper (Trudeau Institute, Saranac Lake, New York, USA)

10.40-11.00
Coffee Break

SESSION 2:
PLENARY SESSION II

Moderator: Ian M. Orme (Colorado State University, Colorado, USA)

11.00-11.30
‘Status report of VPM1002, a novel recombinant BCG vaccine against tuberculosis’
Leander Grode (Vakzine Projekt Management GmbH (VPM), Hannover, Germany)

11.30-12.00
‘Live TB vaccines’
William R. Jacobs (AECOM, Bronx, New York, USA)

12.00-12.30
‘Non-live TB vaccines’
Else Marie Agger and Peter Andersen (SSI, Copenhagen, Denmark)

12.30-14.00
Lunch Break

SESSION 3:
LESSONS LEARNED FROM ANIMAL MODELS

Moderator: Ann Rawkins (Health Protection Agency, Porton Down, Wiltshire, UK)

14.00-14.30
‘New TB vaccine models/testing strategies’
Ann Rawkins (Health Protection Agency, Porton Down, Wiltshire, UK)

14.30-15.00
‘Regulatory T cell responses: The ghost in the machine’
Diane Ordway (Colorado State University, Fort Collins, Colorado, USA)

15.00-15.30
Tea Break

SESSION 3:
CONTINUED

15.30-16.00
‘Refinement of the Macaque model of human tuberculosis through characterisation of the rhesus and cynomologus Macaque species’
Sally Sharpe, Laura Sibley, Andrew White, Karen Gooch, Simon Clark, Alice Marriott, Randall Basaraba, Fergus Gleeson, Helen McShane, Ann Williams, Phillip Marsh and Mike Dennis (Health Protection Agency, Porton Down, Wiltshire, UK)

16.00-16.20
‘Post-exposure vaccines: are they even feasible?’
Ian M. Orme (Colorado State University, Colorado, USA)

16.20-16.50
‘TB vaccine testing in animals: Should risk factors be considered?’
Randall Basaraba (Colorado State University, Colorado, USA)

SESSION 4:
LATE BREAKERS

Moderator: To be confirmed

16.50-17.10
‘Modulation of protection against Mycobacterium tuberculosis by different adjuvanted vaccines’
Rhea N. Coler (IDRI, Seattle, Washington, USA)

17.10-17.30
Mycobacterium bovis and BCG induce different patterns of cytokine and chemokine production in dendritic cells that affect the differentiation of CD4+ T cells’
Aizhen Guo et al. (Huazhong Agricultural University, Wuhan, China)

17.30-17.45
Intradermal device for simplified Mantoux test and BCG vaccination’
Zach Marks (West Pharmaceutical Services, Exton, Pennsylvania, USA)

17.45-18.00
‘Glycosylation of Mycobacterium tuberculosis alanine-proline-rich antigen (Apa) and its effect on antigenicity, immunogenicity and protective efficacy’
Suraj Sable et al. (CDC, Atlanta, Georgia, USA)

18.00-18.15
‘Mycobacterium tuberculosis protein Rv1324, an immunodominant vaccine candidate against tuberculosis’
Subhadra Nanakumar, Sunil Kannanganath, Mani Cheruvu, Bonnie Plikaytis, James Posey, Rama Rao Amara and Suraj Sable (CDC, Atlanta, Georgia, USA)

18.15-18.30
‘A novel particulate vaccine utilising polyester nanoparticles (Bio-Beads) shows efficacy against tuberculosis’
Natalie A. Parlane, Bernd H.A. Rehm, D. Neil Wedlock and Bryce M. Buddle (AgResearch, Hopkirk Research Institute, Palmerston North, New Zealand)

TBV 2012 Welcome Drinks Reception

 

TBV 2012 Delegates

Login details will be supplied after you have registered for the event.


TBV 2012 Sponsors

  • Infectious Disease Research Institute
  • Vakzine Project Management
  • Centers for Disease Control and Prevention
  • Intercell Smart Vaccines

TBV 2012 Downloads

TBV 2012 Leaflet

TBV 2012 Mailing List

Name
E-mail Address
What is 1+4-2?